Trial of JYB1904 Injection in Patients With Perennial Allergic Rhinitis

Inclusion criteria

• . Adult participants ≥18 years and ≤65 years of age at the time of signing the informed consent form (ICF).
• . Physician-diagnosed PAR at screening, symptoms of allergic rhinitis present for a minimum of 2 years.
• . Participants must have been on stable treatment with intranasal corticosteroids (INCS), with or without other background medications for at least four consecutive weeks before randomization, and rTNSS≥6 at screening.
• . Within 1 year prior to screening or at screening, participants must have positive indoor allergen SPT and/or positive antigen-specific serum IgE to indoor allergens . Participants must have clinical symptoms associated with perennial allergen positivity (assessed by SPT) or positive serum antigen-specific IgE at study entry .
• . A participant who has a known history of dermatographism or identified during the SPT may participate in this study with a positive serum antigen-specific IgE test.
• . Participants who have concomitant asthma must use permitted regular asthma treatment during the study and have been stable in the 3 months prior to screening.
• . Is willing and able to comply with daily eDiary.
• . Participants must complete the eDiary during the baseline evaluation period (2 weeks prior to randomization) and meet the following criteria: (1) complete the eDiary for at least 4 days per week; and (2) rTNSS score ≥6 at randomization (average of Day-7 to Day-1).

Exclusion criteria